A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. [electronic resource]
Producer: 20130429Description: 2896-2902 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carboplatin -- administration & dosage
- Carcinoma, Ovarian Epithelial
- Celecoxib
- Cyclooxygenase 2 Inhibitors -- adverse effects
- Disease-Free Survival
- Docetaxel
- Fallopian Tube Neoplasms -- drug therapy
- Female
- Humans
- Middle Aged
- Neoplasm Staging
- Neoplasms, Glandular and Epithelial -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Peritoneal Neoplasms -- drug therapy
- Pyrazoles -- administration & dosage
- Sulfonamides -- administration & dosage
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.